97 related articles for article (PubMed ID: 21039054)
41. Frequency of common CYP3A5 gene variants in healthy Polish newborn infants.
Adler G; Łoniewska B; Parczewski M; Kordek A; Ciechanowicz A
Pharmacol Rep; 2009; 61(5):947-51. PubMed ID: 19904021
[TBL] [Abstract][Full Text] [Related]
42. The influence of CYP3A5 genotype on dexamethasone induction of CYP3A activity in African Americans.
Roberts PJ; Rollins KD; Kashuba AD; Paine MF; Nelsen AC; Williams EE; Moran C; Lamba JK; Schuetz EG; Hawke RL
Drug Metab Dispos; 2008 Aug; 36(8):1465-9. PubMed ID: 18490434
[TBL] [Abstract][Full Text] [Related]
43. The potential implication of SCN1A and CYP3A5 genetic variants on antiepileptic drug resistance among Egyptian epileptic children.
Abo El Fotoh WM; Abd El Naby SA; Habib MS; ALrefai AA; Kasemy ZA
Seizure; 2016 Oct; 41():75-80. PubMed ID: 27498208
[TBL] [Abstract][Full Text] [Related]
44. Functional polymorphisms in the CYP3A4, CYP3A5, and CYP21A2 genes in the risk for hypertension in pregnancy.
Coto E; Tavira B; Marín R; Ortega F; López-Larrea C; Ruiz-Ortega M; Ortiz A; Díaz M; Corao AI; Alonso B; Alvarez V
Biochem Biophys Res Commun; 2010 Jul; 397(3):576-9. PubMed ID: 20617557
[TBL] [Abstract][Full Text] [Related]
45. [Relationship between the genetic polymorphism of CYP3A5 gene and the clinical response to bicyclol in chronic hepatitis B].
Wang RL; Ye XG; Ye LK
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Feb; 22(1):36-8. PubMed ID: 18414696
[TBL] [Abstract][Full Text] [Related]
46. CYP3A5 phenotype-genotype correlations in a British population.
King BP; Leathart JB; Mutch E; Williams FM; Daly AK
Br J Clin Pharmacol; 2003 Jun; 55(6):625-9. PubMed ID: 12814460
[TBL] [Abstract][Full Text] [Related]
47. Association of CYP3A4, CYP3A5 polymorphisms with lung cancer risk in Bangladeshi population.
Islam MS; Mostofa AG; Ahmed MU; Bin Sayeed MS; Hassan MR; Hasnat A
Tumour Biol; 2014 Feb; 35(2):1671-8. PubMed ID: 24085358
[TBL] [Abstract][Full Text] [Related]
48. MDR-1 and CYP3A5 Polymorphisms in Pediatric Idiopathic Nephrotic Syndrome: Impact on Susceptibility and Response to Steroids (Preliminary Results).
Moussa A; Mabrouk S; Hamdouni H; Ajmi M; Tfifha M; Omezzine A; Abroug S; Bouslama A
Clin Lab; 2017 Jul; 63(7):1233-1242. PubMed ID: 28792718
[TBL] [Abstract][Full Text] [Related]
49. Polymorphisms in CYP2C8 and CYP3A5 genes in the Nigerian population.
Adehin A; Bolaji OO; Kennedy MA
Drug Metab Pharmacokinet; 2017 Jun; 32(3):189-191. PubMed ID: 28427759
[TBL] [Abstract][Full Text] [Related]
50. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population.
Fukuen S; Fukuda T; Maune H; Ikenaga Y; Yamamoto I; Inaba T; Azuma J
Pharmacogenetics; 2002 Jun; 12(4):331-4. PubMed ID: 12042671
[TBL] [Abstract][Full Text] [Related]
51. Association of XRCC5 VNTR polymorphism with the development of chronic myeloid leukemia.
Gorre M; Mohandas PE; Kagita S; Annamaneni S; Digumarti R; Satti V
Tumour Biol; 2014 Feb; 35(2):923-7. PubMed ID: 23982877
[TBL] [Abstract][Full Text] [Related]
52. Association of CYP3A5*3 polymorphism with development of acute leukemia.
Rao DN; Manjula G; Sailaja K; Surekha D; Raghunadharao D; Rajappa S; Vishnupriya S
Indian J Hum Genet; 2011 Sep; 17(3):175-8. PubMed ID: 22345989
[TBL] [Abstract][Full Text] [Related]
53. Cytochrome P450 2C19 gene polymorphisms (CYP2C19*2 and CYP2C19*3) in chronic myeloid leukemia patients:
Joshi K; Kaur S; Kumar R
J Biomol Struct Dyn; 2022; 40(19):9389-9402. PubMed ID: 34060427
[TBL] [Abstract][Full Text] [Related]
54. Association of CYP3A5*3 and CYP1A1*2C Polymorphism with Development of Acute Myeloid Leukemia in Egyptian Patients.
Abd El Wahab N; Shafik NF; Shafik RE; Taha ShA; Shafik HE; Darwish AD
Asian Pac J Cancer Prev; 2017 Mar; 18(3):747-752. PubMed ID: 28441709
[TBL] [Abstract][Full Text] [Related]
55. The influence of CYP2C19*2 and CYP3A5*3 variants on the development of depression and effectiveness of therapy: A preliminary study.
Świechowski R; Jeleń A; Pietrzak J; Gałecki P; Szmajda-Krygier D; Balcerczak E
Biomed Pharmacother; 2021 Oct; 142():112055. PubMed ID: 34435592
[TBL] [Abstract][Full Text] [Related]
56. The investigation of allele and genotype frequencies of CYP3A5 (1/3) and P2Y12 (T744C) in Iran.
Azarpira N; Namazi S; Khalili A; Tabesh M
Mol Biol Rep; 2011 Nov; 38(8):4873-7. PubMed ID: 21153923
[TBL] [Abstract][Full Text] [Related]
57. Genotyping of CYP3A5 polymorphisms among Bulgarian patients with sporadic colorectal cancer and controls.
Petrova DT; Yaramov N; Toshev S; Nedeva P; Maslyankov S; von Ahsen N; Oellerich M; Toncheva D
Onkologie; 2007 Nov; 30(11):559-63. PubMed ID: 17992026
[TBL] [Abstract][Full Text] [Related]
58. Construction and verification of CYP3A5 gene polymorphisms using a Saccharomyces cerevisiae expression system to predict drug metabolism.
Lu Y; Zhong H; Tang Q; Huang Z; Jing N; Smith J; Miao R; Li Y; Yuan H
Mol Med Rep; 2017 Apr; 15(4):1593-1600. PubMed ID: 28259948
[TBL] [Abstract][Full Text] [Related]
59. Polymorphisms in the CYP2A6 and ABCC4 genes are associated with a protective effect on chronic myeloid leukemia in the Brazilian Amazon population.
Monte N; Pantoja KBCC; Rodrigues JCG; de Carvalho DC; Azevedo TCB; Pereira EEB; de Assumpção PP; Dos Santos SEB; Fernandes MR; Dos Santos NPC
Mol Genet Genomic Med; 2021 Jul; 9(7):e1694. PubMed ID: 34050721
[TBL] [Abstract][Full Text] [Related]
60. Translational pharmacogenetics and risk management in the cardiovascular arena: CYP3A5*3 model for gene-based drug selection.
Wilke RA
Per Med; 2006 Nov; 3(4):385-390. PubMed ID: 29788593
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
